Biosimilars in inflammatory bowel disease. Issue 11 (18th October 2020)

• Record Type: Journal Article
• Authors: Talathi, Saurabh; Baig, Kondal R. Kyanam Kabir
• Is Part Of: Journal of digestive diseases. Volume 21:Issue 11(2020:Nov.)
• Page Start: 610
• Page End: 620
• Publication Date: 2020-10-18
• Subjects: biologic -- biosimilar pharmaceuticals -- Crohn disease -- inflammatory bowel diseases -- ulcerative colitis; Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.12940
• Languages: English
• ISSNs: 1751-2972

Abstract

Abstract : The advent of biologics has changed outcomes in many chronic conditions, including inflammatory bowel disease (IBD). Biologics have been used for the induction and remission of ulcerative colitis and Crohn's disease for almost two decades and are effective in patients who used to fail conventional treatment with steroids, immunomodulators. The use of biologics in the treatment of IBD has increased over the last few years, partly due to the rise in its incidence and the use of biologics as a first‐line treatment in severe disease as well as in complicated diseases like penetrating/fistulating Crohn's disease. However, their use is associated with a significant burden to the society with respect to healthcare costs, resulting in the premature discontinuation of therapy in some patients, leading to exacerbations and complications. The introduction of biosimilars a decade ago seems to be a promising approach to reducing the costs related to therapy. Since their introduction, numerous studies conducted in adults and some in children show the efficacy of biosimilars with a similar side‐effect profile to biologics. This review discusses the history of biosimilars in the treatment of IBD, enumerates several such studies and discusses the possibility of using biosimilars in the future. Abstract : The use of biologics in inflammatory bowel disease confers a significant financial burden on society. The introduction of biosimilars appears to be a promising alternative to biologics. Since the introduction of biosimilars several studies have reported their efficacy and safety data.